Cord Blood-Derived CD133+ Cells Improve Cardiac Function After Myocardial Infarction

Main Category: Stem Cell Research
Also Included In: Biology / Biochemistry;  Cardiovascular / Cardiology
Article Date: 05 Feb 2010 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Researchers at the Pontifícia Universidade Catolica do Parana and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence. HUCB-derived EPCs could be an alternative to rescue impaired stem cell function in the sick and elderly. The results, which appear in the January 2010 issue of Experimental Biology and Medicine, show that expanded cells ex vivo exhibited increased expression of mature endothelial cells markers and formed tubule-like structures in vitro. Only the expanded cells expressed VEGF mRNA.

Cells were expanded up to 70-fold during 60 days of culture, and they retained their functional activity. A significant improvement was observed in left ventricular ejection fraction for purified and expanded cells. In summary, CD133+ cells were purified from HUCB, expanded in vitro without losing their biological activity, and both purified and expanded cells showed promising results for use in cellular cardiomyoplasty. However, further pre-clinical testing should be performed to determine whether expanded CD133+ cells have any clinical advantages over purified CD133+ cells.

Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "This study suggests that the use of human umbilical cord blood-derived purified and expanded CD133+ cells may show promise for use in cellular cardiomyoplasty. This finding needs subsequent pre-clinical testing but may prove to be very important in future treatments".

Source:
Dr. Alexandra Senegaglia
Society for Experimental Biology and Medicine

Article adapted by Medical News Today from original press release.
Visit our stem cell research section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Dr. Alexandra Senegaglia. "Cord Blood-Derived CD133+ Cells Improve Cardiac Function After Myocardial Infarction." Medical News Today. MediLexicon, Intl., 5 Feb. 2010. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/178218.php>

APA
Dr. Alexandra Senegaglia. (2010, February 5). "Cord Blood-Derived CD133+ Cells Improve Cardiac Function After Myocardial Infarction." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/178218.php.

Please note: If no author information is provided, the source is cited instead.


Stem Cell Research

What are Stem Cells?

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: embryonic stem cells and adult stem cells Read more...

Most Popular Articles



Follow Our Stem Cell Research News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Stem Cell Research Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »